Geode Capital Management
CBAY

Geode Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Geode Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,380,105
Closed -$56.2M – 4657
2023
Q4 		$56.2M Buy
2,380,105
+304,549
+15% +$5.42M 0.01% 1271
2023
Q3 		$31M Buy
2,075,556
+220,086
+12% +$2.92M ﹤0.01% 1539
2023
Q2 		$20.3M Buy
1,855,470
+950,512
+105% +$8.85M ﹤0.01% 1844
2023
Q1 		$7.89M Buy
904,958
+115,044
+15% +$921K ﹤0.01% 2397
2022
Q4 		$4.95M Buy
789,914
+4,949
+0.6% +$18.8K ﹤0.01% 2673
2022
Q3 		$2.75M Buy
784,965
+72,387
+10% +$260K ﹤0.01% 2972
2022
Q2 		$2.1M Sell
712,578
-604,370
-46% -$1.44M ﹤0.01% 3095
2022
Q1 		$4.09M Buy
1,316,948
+165,743
+14% +$522K ﹤0.01% 2915
2021
Q4 		$3.89M Buy
1,151,205
+44,114
+4% +$167K ﹤0.01% 3031
2021
Q3 		$4.04M Sell
1,107,091
-38,514
-3% -$152K ﹤0.01% 3035
2021
Q2 		$4.99M Sell
1,145,605
-11,369
-1% -$50.4K ﹤0.01% 2911
2021
Q1 		$5.25M Buy
1,156,974
+117,409
+11% +$632K ﹤0.01% 2768
2020
Q4 		$5.97M Buy
1,039,565
+22,815
+2% +$173K ﹤0.01% 2506
2020
Q3 		$7.36M Sell
1,016,750
-39,253
-4% -$210K ﹤0.01% 2158
2020
Q2 		$3.69M Sell
1,056,003
-31,180
-3% -$90K ﹤0.01% 2505
2020
Q1 		$1.61M Buy
1,087,183
+59,263
+6% +$99.5K ﹤0.01% 2794
2019
Q4 		$2.01M Buy
1,027,920
+94,316
+10% +$354K ﹤0.01% 3006
2019
Q3 		$4.78M Buy
933,604
+52,891
+6% +$320K ﹤0.01% 2407
2019
Q2 		$6.3M Buy
880,713
+104,633
+13% +$1.18M ﹤0.01% 2248
2019
Q1 		$10.3M Buy
776,080
+150,453
+24% +$1.6M ﹤0.01% 1877
2018
Q4 		$4.92M Buy
625,627
+32,337
+5% +$308K ﹤0.01% 2240
2018
Q3 		$6.57M Buy
593,290
+32,227
+6% +$400K ﹤0.01% 2191
2018
Q2 		$7.53M Buy
561,063
+180,004
+47% +$2.25M ﹤0.01% 2080
2018
Q1 		$4.95M Buy
381,059
+100,796
+36% +$1.25M ﹤0.01% 2239
2017
Q4 		$2.58M Hold
280,263
– – ﹤0.01% 2612
2017
Q3 		$2.26M Buy
280,263
+114,142
+69% +$772K ﹤0.01% 2675
2017
Q2 		$956K Sell
166,121
-2,407
-1% -$10.2K ﹤0.01% 3124
2017
Q1 		$724K Buy
168,528
+70,232
+71% +$201K ﹤0.01% 3160
2016
Q4 		$170K Hold
98,296
– – ﹤0.01% 3668
2016
Q3 		$190K Hold
98,296
– – ﹤0.01% 3626
2016
Q2 		$171K Hold
98,296
– – ﹤0.01% 3642
2016
Q1 		$132 Hold
98,296
– – ﹤0.01% 3753
2015
Q4 		$166K Buy
98,296
+12,500
+15% +$20.4K ﹤0.01% 3743
2015
Q3 		$166K Buy
85,796
+36,774
+75% +$100K ﹤0.01% 3743
2015
Q2 		$131K Hold
49,022
– – ﹤0.01% 3708
2015
Q1 		$339K Buy
49,022
+15,326
+45% +$147K ﹤0.01% 3366
2014
Q4 		$331K Buy
+33,696
New +$271K ﹤0.01% 3372

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Geode Capital Management's CBAY Position: Q1 2024 in Review

Geode Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 2,380,105 shares — an estimated $56.2M sold.

Geode Capital Management first reported a position in CBAY in Q4 2014 and held it in 37 quarters. The position peaked at $56.2M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Geode Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Geode Capital Management sold 2,380,105 Cymabay Therapeutics shares in Q1 2024, an estimated $56.2M.
  • Geode Capital Management first reported a position in Cymabay Therapeutics in Q4 2014 and held it in 37 quarters.
  • Geode Capital Management's Cymabay Therapeutics position peaked at $56.2M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Geode Capital Management's 13F filing for Q1 2024, filed 13 May 2024.